1056 GMT - Alcon's third-quarter results were worse than expected and raise questions about the eyecare specialist's outlook for next year, Jefferies analysts say in a note. Investors had lower expectations for the third-quarter results, but the update was still worse than anticipated, the analysts say. Revenue missed consensus estimates and full-year guidance was mostly lowered at the midpoint of the new narrowed ranges, even if third-quarter earnings beat forecasts, they add. Competitive pressure that has weighed on sales of Alcon's implantable products could persist into the fourth quarter, Jefferies says. Zurich-listed shares fall 5.6%.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.